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ABSTRACT
The Surgery Treatment Modality Committee of the Korean Gynecologic Oncology Group 
has determined to develop a surgical manual to facilitate clinical trials and to improve 
communication between investigators by standardizing and precisely describing operating 
procedures. The literature on anatomic terminology, identification of surgical components, 
and surgical techniques were reviewed and discussed in depth to develop a surgical manual 
for gynecologic oncology. The surgical procedures provided here represent the minimum 
requirements for participating in a clinical trial. These procedures should be described in 
the operation record form, and the pathologic findings obtained from the procedures should 
be recorded in the pathologic report form. Here, we describe surgical procedure for ovarian, 
fallopian tubal, and peritoneal cancers.
Keywords: Manuals as Topic; Gynecologic Surgical Procedures; Ovarian Neoplasms
INTRODUCTION
This surgical manual is for all cases of suspicious ovarian, tubal, and peritoneal cancers. It is 
organized into five sections including surgical procedures in ovarian, tubal, and peritoneal 
cancers, perioperative preparation, operation record form (ORF), pathologic report form 
(PRF), and tumor burden index (TBI).
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We emphasize that surgical procedures in this manual represent the minimum requirements 
for clinical trials. This manual is the first version and will be updated to accommodate various 
clinical trials.
SURGICAL PROCEDURES IN OVARIAN, TUBAL, AND 
PERITONEAL CANCERS
In cases of suspected early stage diseases, the primary objective of surgical staging of 
ovarian, tubal, and peritoneal cancers is to establish adjuvant treatment strategies and in 
cases of suspected advanced stage diseases, optimal debulking surgery of ovarian, tubal, and 
peritoneal cancers should be achieved with acceptable morbidity.
1. Contents of surgical procedure
Midline vertical abdominal incision from the pubic symphysis to the xiphoid process is 
recommended for adequate exposure and evaluation of the whole abdomen. Minimally invasive 
surgical techniques (laparoscopy or robotic surgery) may be performed to accomplish surgical 
staging for selected patients based on preoperative imaging, such as computed tomography 
(CT), magnetic resonance imaging, or positron emission tomography/CT [1-7].
Prior to systemic exploration, free peritoneal fluid should be aspirated for cytology. Washing 
cytology with at least 20 to 50 mL of saline should be obtained in case of no free fluid in 
abdominal cavity. Patients with stage III or IV disease do not require cytologic assessment [1,6,8].
A systematic exploration is recommended to check the tumor involvement in the pelvic and 
abdominal organs, and peritoneal surface; clockwise or counterclockwise examination is 
usually performed from the cecum cephalad along the right paracolic gutter. The followings 
are investigated sequentially: ascending colon, liver, right diaphragm, stomach, lesser sac, 
porta hepatis, transverse colon, left diaphragm, spleen, distal pancreas, descending colon, 
left paracolic gutter, rectosigmoid colon, uterus, ovary, and bladder [1,6].
Biopsy should be performed at any suspicious site with tumor involvement if the suspected 
disease affects the surgical staging or adjuvant treatment. Multiple intraperitoneal biopsies 
from the cul-de-sac, vesical peritoneum, both pelvic sidewalls, and both paracolic gutters 
should be conducted in case of no evidence of disease [1,6].
Ovarian tumor should be removed intact, and frozen biopsy is strongly recommended during 
operation, if possible. Hysterectomy with bilateral salpingo-oophorectomy is recommended. 
Tumors throughout the abdomen should be removed as much as possible. Omentectomy 
should be fulfilled during surgical staging [9].
All visible and palpable tumor volume should be minimized as much as possible with 
debulking operations, such as visceral and parietal peritonectomy: peritoneal stripping, 
diaphragmatic resection, cholecystectomy, hepatic resection, splenectomy, distal 
pancreatectomy, appendectomy, bowel resection, urinary tract resection, partial cystectomy, 
and lymph node dissection [7,10-15].
Retroperitoneal inspection should be carried out to check for metastasis to pelvic and  
para-aortic lymph nodes. Pelvic and para-aortic lymph node should be systematically 
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evaluated in case of stage I or II, and the extent of retroperitoneal lymph node dissection 
could be modified based on the degree of the intraperitoneal residual tumor and the status of 
the lymph node on the preoperative image (see the description of lymphadenectomy in ORF) 
[16-18]. Unilateral salpingo-oophorectomy with preservation of the uterus may be considered 
to preserve fertility for selected patients [19,20].
Before the neoadjuvant chemotherapy (NAC), the methods for pathologic diagnosis of 
ovarian, tubal, and peritoneal cancers are recommended as follows: laparoscopic biopsy, 
image-guided gun biopsy or aspiration, or cell block from the aspiration of ascites. In case of 
interval debulking surgery, the traced lesion after NAC should be evaluated carefully and its 
management should be recorded clearly [21,22].
Medical record of surgery is recommended to describe the extent of initial tumors before 
surgery at pelvis, mid-abdomen, or upper abdomen. Demonstration of the status of residual 
tumors after surgery, complete or incomplete, is recommended to identify the size and 
number of remaining lesions. Photograph or video recording is one of the methods used 
to describe the preoperative and postoperative tumor, and surgical procedures. We provide 
schematic overview of this surgical manual (Table 1).
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Table 1. Schematic overview of surgical procedure in ovarian, tubal, and peritoneal cancers
Recommendation for surgical technique in ovarian, tubal, and peritoneal cancer
Preparation
Preoperative intravenous antibiotics injection with adequate bowel preparation is recommended
Assessment
• A midline vertical incision is recommended. Minimally invasive techniques (laparoscopy, robotic) may be performed for selected patients
• Systematic exploration for tumor involvement on the pelvic and abdomen organs, and peritoneum
• Aspiration of peritoneal fluid or washing cytology in case of no free peritoneal fluid (pelvis, paracolic gutters and infradiaphragmatic area)
• Inspection and palpation of all peritoneal surfaces including diaphragms, serosa, and mesentery of the entire gastrointestinal tract
• Random biopsies in the absence of any suspicious area
• Intraoperative frozen biopsy (recommended)
Surgery
• Bilateral salpingo-oophorectomy, but unilateral salpingo-oophorectomy may be considered in case of preserving fertility
• Hysterectomy
• Omentectomy
• Pelvic and para-aortic lymph node dissection
The following procedures can be considered for the optimal cytoreduction
• Bowel resection
• Stripping and/or resection of the diaphragm or other peritoneal surfaces
• Splenectomy
• Appendectomy
• Partial cystectomy, uretero-neoureterostomy, or ureteroneocystotomy
• Partial hepatectomy
• Partial gastrectomy
• Cholecystectomy
• Distal pancreatectomy
• Suprarenal, porta hepatis, cardiophrenic, internal mammary, axillary, or supraclavicular lymph node dissection
* All visible and palpable tumor should be tried to be resected by experienced gynecologic oncologists or multidisciplinary surgical team if surgical procedure 
is feasible with acceptable morbidity
Special circumstances
• Before the neoadjuvant chemotherapy (NAC), the method for microscopic diagnosis of ovarian, tubal, and peritoneal cancer is suggested as follows: 
laparoscopic biopsy, image-guided gun biopsy or aspiration, and cell block from the aspiration of ascites
• In case of interval debulking surgery, the traced lesion after NAC is suggested to be explored surgically
PERIOPERATIVE PREPARATION
We provide perioperative preparation that includes antibiotic prophylaxis, prevention of 
thromboembolic disease, and patient’s position.
1. Antibiotic prophylaxis
The use of prophylactic antibiotics before surgery is suggested for the prevention of 
postoperative gynecological infections. Antibiotics are recommended to be given 
immediately before skin incision. Antibiotic regimen can be selected according to the 
types of surgery or surgeon’s preference. Additional use of prophylactic antibiotics is 
recommended to maintain effective levels of intravascular antibiotics in certain clinical 
situations, like massive bleeding or prolonged operative time [23,24].
2. Prevention of thromboembolic disease
Prophylaxis with anti-coagulants can be selectively suggested to cancer patients with high 
risk of deep-vein thrombosis and thromboembolic disease (Table 2) [25-29].
3. Patient position
If concomitant bowel resection is expected during operation, lithotomy position is 
recommended for patients who undergo laparotomy, and gel pads can be used for prevention 
of pressure sores [12].
OPERATION RECORD FORM
In the debulking surgery for the advanced stage disease, multidisciplinary surgical teams 
including gynecologic oncologic surgeons, colorectal surgeons, hepatobiliary surgeons, and 
even thoracic surgeons usually perform a lot of surgical procedures to minimize residual lesion 
and these surgical procedures should be described systematically and properly in the operation 
record. ORF for ovarian tubal and peritoneal cancers has been established on the basis of 
the Synoptic Operative Template for Ovarian Cancer of National Cancer Center of Korea. 
Standardized ORF may encourage to record all required information and surgical procedures 
and can save time. In the clinical trial setting, by looking at ORF, investigators can identify all 
procedures. ORF includes the following information (Fig. 1, Supplementary Fig. 1).
TUMOR BURDEN INDEX
To estimate perioperative tumor burden, Korean Gynecologic Oncology Group (KGOG) developed 
TBI by modifying the peritoneal carcinomatosis index of Korean National Cancer Center. 
The peritoneal cavity is divided into nine well defined regions (Fig. 2, Supplementary Fig. 2). 
Investigators should describe pre- and post-operative largest tumor diameter, operative finding, 
operation name in each region, and the largest residual tumor at the end of the operation.
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Table 2. The methods for the prevention of thromboembolic events [25-29]
Class Example
Pharmacologic Unfractionated heparin, low-molecular weight heparin, fondaparinux, warfarin, dextran
Mechanical External pneumatic compression, elastic stocking
Behavioral Short preoperative hospitalization, early postoperative mobilization, feet elevation above heart level
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Operationrecordformforovarian,tubal,andperitonealcancers
 
 
 
General information
 
Patient ID
Name
Operation date
Operator
Assistant
FIGOstaging
□ IA □ IB □ IC1 □ IC2 □ IC3 □ IIA □ IIB □ IIIA1 (i) □ IIIA1 (ii) □ IIIA2 □ IIIB □ IIIC □ IVA □ IVB
 
Primary site
□ Ovary □ Fallopian tube □ Peritoneum □Unknown
 
Disease status
□ Primary disease □ After neoadjuvant chemotherapy
□ Re-staging □ Recurrent disease
□ Others ( )
 
Preoperative tumor marker
□ CA-125 ( ) □ CA-19-9 ( ) □ HE-4 ( ) □ CEA ( ) □ Others ( )
 
Anesthesia
□ General □ Spinal □ Epidural □ Local □ Others
 
Patient's position
□ Supine □ Lithotomy □ Others
 
Approach
Laparotomy
□ Midline incision from xiphoid process to symphysis pubis
□ Lower midline incision
□ Pfannenstiel's incision □Maylard incision □ Others ( )
 
Minimally invasive surgery
□ Laparoscopic □ Port numbers ( )
□ Robotic □ Port numbers ( )
Conversion □ No
□ Yes from ( ) to ( )
Reason □ Bleeding □ Adhesion □ Organ injury
□ Other organ invasion □ Others ( )
 
Operation
 
 
Fertility preservation □ No □ Yes  
Hysterectomy □ No □ Yes  
 □ Type A □ Type B □ Type C
 
 
 
 
 
Salpingo-oophorectomy, Left                           □ No                             □ Biopsy                      □ Yes
Right □ No □ Biopsy □ Yes
Peritonectomy        □ No                           □ Yes                          □ Biopsy
Pelvic □ Left side wall □ Right side wall □ Bladder serosa □Cul-de-sac
Abdominal □ Left □ Right
Diaphragmatic       □ Left                          □ Right
Omentectomy           □ No                              □ Yes
□ Biopsy □ Infracolic □ Total
Bowel resection □ No □ Yes (specify, if yes: )
Prophylactic stomy □ No □ Yes (specify, if yes: )
Permanent stomy □ No □ Yes (specify, if yes: )
Splenectomy           □ No                           □ Yes
Other organ resection □ No □ Yes (specify, if yes: )
Video-assisted thoracic surgery □ No □ Yes (specify, if yes: )
Lymphadenectomy (KGOG classification)
□ None
Pelvic LN/Level 1                    □ Rt LNS          □ Rt LND          □ Lt LNS           □ Lt LND
Common iliac LN/Level 2 □ Rt LNS         □ Rt LND         □ Lt LNS         □ Lt LND              
Para-aortic LN (infra-IMA)/Level 3 □ LNS              □ LND
Para-aortic LN (infra-renal)/Level 4 □ LNS              □ LND
□ Debulking (specify site: )
□ Others ( )
Other operation (procedure: ) (surgeon: )
 
Intraoperative findings
 
 
Frozen biopsy
Ascites
Adhesion
Ovarian tumor
Intraperitoneal tumor
Lymph node enlargement
Extraperitoneal tumor
□ No
□ No
□ No
□ No
□ No
□ No
□ No
□ Yes (specify, if yes: )
□ Yes ( mL)
□ Yes (specify, if yes: )
□ Yes (largest tumor size cm/residual tumor size cm)
□ Yes (largest tumor size cm/residual tumor size cm)
□ Yes (specify, if yes: )
□ Yes (site:     largest tumor size     cm/residual tumor size     cm)
Largest residual tumor   
□ No gross residual
Anti-adhesive used
□ ≤0.5 cm □ ≤1 cm □ ≤2 cm □ >2 cm
□ No □ Yes ( )
Intraoperative injury   
□ Ureter  (specify, if yes: )
□ Vessel
□ Bowel
□ Others
 (specify, if yes: )
(specify, if yes: )
(specify, if yes: )
 
 
 
 
 
Estimated blood loss ( mL)
Transfusion □ No □Yes
(p-RBC pint, Plt conc pint, FFP pint, WB pint)
Drain □ No □ Yes
□ LLQ □ RLQ □ LUQ □ RUQ □ Others ( )
Gauze count □ Checked □ Not checked
Wound closure
Peritoneum □ No □Yes
Fascia □ No □Yes
Subcutaneous □ No □Yes
Skin □ No □Yes
Remarks
Fig. 1. Operation record form for ovarian, tubal, and peritoneal cancers. CA-125, cancer antigen 125; CA-19-9, cancer antigen 19-9; CEA, carcinoembryonic 
antigen; FFP, fresh frozen plasma; FIGO, International Federation of Gynecology and Obstetrics; HE-4, human epididymis protein 4; KGOG, Korean Gynecologic 
Oncology Group; LN, lymph node; LND, lymph node dissection; LNS, lymph node sampling; LLQ, left lower quadrant; Lt, left; LUQ, left upper quadrant; Plt conc, 
platelet concentration; p-RBC, packed red blood cells; RLQ, right lower quadrant; Rt, right; RUQ, right upper quadrant; WB, whole blood.
 
 
Tumorburdenindex(TBI) forovarian,tubal,andperitonealcancers
 
 
 
Region
 
 
Location
Pre-operative
largest
diameter 
(cm)
Post-operative
largest
diameter
(cm)
 
Findings 
(describe)
 
Operation
name
 
Others
(describe)
1
Omentum
 
Omentum
     
 
2
LUQ
Left diaphragm
Spleen
Distal pancreas
     
 
3
Epigastric
Lesser omentum & lesser sac
Stomach
Falciform ligament
Porta hepatis
     
 
 
4
RUQ
Right diaphragm
Liver
Gall bladder
Morrison pouch
(between right liver and kidney)
     
 
 
5
Colon
Sigmoid colon, Rectum
Cecum, Appendix
Ascending colon, Hepatic flexure, 
Transverse colon,
Descending colon, Splenic flexure, 
Mesentery
     
6
Small bowel
Small bowel
Mesentery
     
7
Para-colic
gutter
 
Right paracolic gutter
Left paracolic gutter
     
 
8
Pelvis
Right ovary & pelvic peritoneum
Left ovary & pelvic peritoneum
Uterus
Urinary bladder
     
 
 
9
LN
Pelvic LN/L1      
Common iliac LN/L2      
PALN (infra-IMA)/L3      
PALN (infra-renal)/L4      
 
 
Other
sites
 
Others (describe)
     
      
 
 
The largest
residual tumor           None ( ) or mm, Location
Fig. 2. Korean Gynecologic Oncology Group tumor burden index (TBI) for ovarian, tubal, and peritoneal cancers. IMA, inferior mesenteric artery; LN, lymph 
node; LUQ, left upper quadrant; PALN, paraaortic lymph node; RUQ, right upper quadrant.
PATHOLOGIC REPORT FORM
Surgery Treatment Modality Committee of KGOG collected and analyzed several ovarian 
cancer PRFs from committee members’ hospitals and decided that PRF should be made with 
Gynecologic Pathology Study Group. There were in-depth discussions with the Gynecologic 
Pathology Study Group about how to develop the PRF for ovarian, tubal and peritoneal 
cancer. PRF includes the following information (Fig. 3, Supplementary Fig. 3).
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Pathologic report form for ovarian, tubal, and peritoneal cancers
 
 
 
Operation:
□ Oophorectomy (right/left/bilateral) □ Salpingo-oophorectomy (right/left/bilateral)
□ Salpingectomy (right/left/bilateral) □ Hysterectomy
□ Omentectomy □ Peritoneal biopsy (specify)
□ Lymph node sampling/dissection (specify) □ Other (specify)
 
 
Primary tumor site:
□ Ovary (right/left/bilateral) □ Fallopian tube (right/left/bilateral)
□ Peritoneum □ Other (specify)
 
 
Tumor size:
 
Greatest dimension: cm
 
Additional dimensions (optional): × cm
 
Fragmented: gm, and/ or × × cm in aggregates
 
 
Histologic type:
□ High-grade serous carcinoma □ Low-grade serous carcinoma
□ Serous tubal intraepithelial carcinoma (STIC) □ Mucinous carcinoma (expansile/infiltrative)
□ Endometrioid carcinoma □ Clear cell carcinoma
□ Malignant Brenner tumor □ Seromucinous carcinoma
□ Undifferentiated carcinoma □ Carcinosarcoma
□ Other (specify)
 
 
Histologic grade:
□ G1 □ G2 □ G3 □ Not applicable □ Cannot be assessed
 
 
Tumor extension:
 
(1)Ovarian surface involvement: absent/present (right/left/bilateral)
 
(2) Fallopian tubesurface involvement: absent/present(right/left/bilateral)
 
(3) Ovarian capsule: intact/ruptured/opened (right/left/bilateral)
(4) Pelvic extension below pelvic brim: absent/present
(uterus, ovary, fallopian tube, pelvic peritoneum, urinary bladder, sigmoid colon, rectum, anterior cul-de-sac,
posterior cul-de-sac, right pelvic wall, left pelvic wall, other [specify])
(5)Involvement of extrapelvic peritoneum: absent/present (Greatest metastatic tumor dimension:      mm)
(omentum, abdominal peritoneum, stomach, small bowel, mesentery, appendix, cecum, ascending colon,
transverse colon, right paracolic gutter, descending colon, left paracolic gutter, diaphragm, liver surface,
liver parenchyma, spleen surface, spleen parenchyma, other [specify])
 
Level 3, para-aortic infra-IMA: ( / )
Level 4, para-aortic infra-renal: ( / )
Other (specify)   
 
 
 
 
 
Lymph node metastasis:□Absent □ Present
 
Greatest metastatic tumor dimension: mm  
Extranodal extent:□ Absent,□ Present ( mm)
Level 1, external and internal iliac (including obturator): Right ( /
 
 
), Left (
 
 
/
 
 
)
Level 2, common iliac (including presacral): Right ( / ), Left ( / )   
 
 
 
 
 
 
Vascular/lymphatic invasion:
□ Absent □ Present □ Indeterminate
 
 
Additional pathologic findings:
□ Endometriosis (specify site) □ Endosalpingiosis (specify site) □ Other (specify)
 
 
Cytology (optional):
Peritoneal washing: □ No malignant cells □ Malignant cells □ Other (specify)
Ascites: □ No malignant cells □ Malignant cells □ Other (specify)
 
 
pTNM: pT( ) pN( ) M( )
Fig. 3. Pathologic report form for ovarian, tubal, and peritoneal cancers. pTNM, pathological tumor node metastasis.
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